Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

Last updated: 18 Dec 2015

Secukinumab

Summary
Trade name: 
Cosentyx
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Class: 
Immunosuppressor
(2)
Immunosuppressive monoclonal antibodies: current and next generation.
Focosi D, Maggi F, Pistello M, Boggi U, Scatena F
Clin Microbiol Infect. 2011 Dec; 17(12):1759-68. Epub 2011 Oct 13. PMID: 21995285. Abstract
Target: 
Interleukin 17A, a proinflammatory cytokine that is produced by T helper 17 cells and that is associated with autoimmune diseases
(5)
Averting inflammation by targeting the cytokine environment.
Kopf M, Bachmann MF, Marsland BJ
Nat Rev Drug Discov. 2010 Sep; 9(9):703-18. PMID: 20811382. Abstract
(6)
Structure and signalling in the IL-17 receptor family.
Gaffen SL
Nat Rev Immunol. 2009 Aug; 9(8):556-67. Epub 2009 Jul 03. PMID: 19575028. Abstract
(7)
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Novartis, 3 Oct 2013
Accessed on 28 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml.
Status for MS: 
Phase II trials are underway
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Administration: 
Intravenous; doses ranged from 3 to 10 mg per kg, given as a 2-hour intravenous infusion either once or twice (3 weeks apart) in clinical studies
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Given in monthly subcutaneous injections (25 mg to 300 mg) in a clinical trial for rheumatoid arthritis
(20)
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee S-H, Codding CE, Kellner H, et al.
Ann Rheum Dis. 2013 Jun; 72(6):863-9. Epub 2012 Jun 23. PMID: 22730366. Abstract
Commercial: 
Developed by Novartis Pharmaceuticals
(23)
Biologics at Novartis
Novartis
Accessed on 29 Oct 2013 from http://www.nibr.com/cs/groups/public/@nibr_com/documents/document/n_prod_200370.pdf.
Clinical trials have been sponsored by Novartis Pharmaceuticals
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Approved in Japan for treating adults with psoriasis or psoriatic arthritis (26 December 2014)
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Approved in the US and EU for treating moderate-to-severe plaque psoriasis (early 2015)
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Names
Name: 
Secukinumab
Trade name: 
Cosentyx
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Synonyms: 
AIN 457
(4)
ChemIDplus Advanced
United States National Library of Medicine
Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp.
AIN457
(4)
ChemIDplus Advanced
United States National Library of Medicine
Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp.
UNII-DLG4EML025
(4)
ChemIDplus Advanced
United States National Library of Medicine
Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp.
Systematic name: 
Immunoglobulin G1, anti-(human interleukin-17A (IL-17, cytotoxic T- lymphocyte-associated antigen 8))
(4)
ChemIDplus Advanced
United States National Library of Medicine
Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp.
Human monoclonal AIN457 gamma1 heavy chain (230-215')-disulfide with human monoclonal AIN457 kappa light chain dimer (236-236'':239-239'')-bisdisulfide
(4)
ChemIDplus Advanced
United States National Library of Medicine
Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp.
Physiology
Class: 
Immunosuppressor
(2)
Immunosuppressive monoclonal antibodies: current and next generation.
Focosi D, Maggi F, Pistello M, Boggi U, Scatena F
Clin Microbiol Infect. 2011 Dec; 17(12):1759-68. Epub 2011 Oct 13. PMID: 21995285. Abstract
Target: 
Interleukin 17A, a proinflammatory cytokine that is produced by T helper 17 cells and that is associated with autoimmune diseases
(5)
Averting inflammation by targeting the cytokine environment.
Kopf M, Bachmann MF, Marsland BJ
Nat Rev Drug Discov. 2010 Sep; 9(9):703-18. PMID: 20811382. Abstract
(6)
Structure and signalling in the IL-17 receptor family.
Gaffen SL
Nat Rev Immunol. 2009 Aug; 9(8):556-67. Epub 2009 Jul 03. PMID: 19575028. Abstract
(7)
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Novartis, 3 Oct 2013
Accessed on 28 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml.
Properties: 
Recombinant, fully human G1κ (IgG1κ) monoclonal antibody that binds and neutralizes the proinflammatory cytokine interleukin 17A
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
(5)
Averting inflammation by targeting the cytokine environment.
Kopf M, Bachmann MF, Marsland BJ
Nat Rev Drug Discov. 2010 Sep; 9(9):703-18. PMID: 20811382. Abstract
(7)
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Novartis, 3 Oct 2013
Accessed on 28 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml.
(8)
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD, Lee DM, Kolbinger F, Antoni C
Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii116-23. Epub 2012 Dec 19. PMID: 23253932. Abstract
Half life is expected to be 3 to 4 weeks
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Molecular weight, 147.94 kDa
(3)
Statement on a nonproprietary name adopted by the USAN Council
American Medical Association
Accessed on 28 Oct 2013 from http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf.

Mechanisms/Effects

Human: 
Has broad anti-inflammatory effects in individuals with psoriasis
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Reduces the expression of genes encoding a variety of cytokines and chemokines associated with autoimmunity in psoriasis plaque samples
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Reduces the expression of genes encoding interleukin 17A (IL-17A) and IL-22, as shown by reverse transcription PCR and microarray analysis, in psoriasis plaque samples
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Reduces the expression of genes encoding cytokines that act upstream of interleukin 17A (IL-17A), such as IL-12B, or downstream of IL-17A, such as chemokine (C-C motif) ligand 20, as shown by reverse transcription PCR and microarray analysis, in psoriasis plaque samples
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Reduces the increase in the pro-inflammatory cytokine interleukin 6 (IL6) that is induced by IL17A and IL17A/tumor necrosis factor-alpha in human astrocytes
(25)
The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.
Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK
Glia. 2014 Feb 14. PMID: 24677511. Abstract
Reduces the increase in the nuclear translocation of the transcription factor NF-κB that is induced by IL17A and IL17A/tumor necrosis factor-alpha in human astrocytes
(25)
The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.
Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK
Glia. 2014 Feb 14. PMID: 24677511. Abstract
Reduces the number of T cells in psoriatic skin lesions
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Animal: 
Monoclonal antibody that neutralizes interleukin 17 (not secukinumab per se) ameliorates the course of murine experimental autoimmune encephalomyelitis
(9)
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.
Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R
Cell Immunol. 2005 Oct; 237(2):123-30. Epub 2005 Dec 28. PMID: 16386239. Abstract
Human-anti-human interleukin 17A antibody delays progression of neurological disease in some cases in a marmoset experimental autoimmune encephalomyelitis model, but not in a statistically significant manner
(10)
Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.
Kap YS, Jagessar AS, van Driel N, Blezer E, Bauer J, van Meurs M, Smith P, Laman JD, 't Hart BA
J Neuroimmune Pharmacol. 2011 Sep; 6(3):341-53. Epub 2010 Aug 12. PMID: 20700661. Abstract
Regulatory and Commercial Status
Status for MS: 
Phase II trials are underway
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Highest status achieved (for any condition): 
Approved
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Other uses: 
Approved for treating moderate-to-severe plaque psoriasis (2015)
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Effective in treating moderate-to-severe plaque psoriasis in Phase II and Phase III trials
(7)
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Novartis, 3 Oct 2013
Accessed on 28 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml.
(17)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P, Sigurgeirsson B, Thaci D, Ortonne J-P, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, et al.
Br J Dermatol. 2013 Feb; 168(2):402-11. PMID: 23362969. Abstract
(18)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB
Br J Dermatol. 2013 Feb; 168(2):412-21. Epub 2013 Jan 18. PMID: 23106107. Abstract
Reduced signs of active ankylosing spondylitis in a Phase II trial
(19)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, et al.
Lancet. 2013 Sep 12. PMID: 24035250. Abstract
Caused clinically relevant responses in the immune-mediated diseases psoriasis, rheumatoid arthritis, and chronic noninfectious uveitis in proof-of-concept clinical trials
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Did not meet primary efficacy endpoints in 3 placebo-controlled Phase III trials for different forms of noninfectious uveitis, but there may have been a positive effect in terms of decreasing the use of concomitant immunosuppressive medication
(16)
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, Androudi S
Ophthalmology. 2013 Apr; 120(4):777-87. Epub 2013 Jan 03. PMID: 23290985. Abstract
Did not meet the primary endpoint (the American College of Rheumatology 20% response) in a Phase II trial for rheumatoid arthritis, although the disease activity decreased with some doses
(20)
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee S-H, Codding CE, Kellner H, et al.
Ann Rheum Dis. 2013 Jun; 72(6):863-9. Epub 2012 Jun 23. PMID: 22730366. Abstract
Associated with an improvement in rheumatoid arthritis symptoms in a Phase II, placebo-controlled trial
(24)
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee S-H, Codding CE, Kellner H, Ikawa T, et al.
J Rheumatol. 2014 Mar; 41(3):414-21. Epub 2014 Jan 15. PMID: 24429175. Abstract
Found to be ineffective for moderate to severe Crohn's disease in a placebo-controlled trial
(21)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al.
Gut. 2012 Dec; 61(12):1693-700. Epub 2012 May 17. PMID: 22595313. Abstract
Did not reduce the effects of ozone-induced airway neutrophilia
(22)
The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers.
Kirsten A, Watz H, Pedersen F, Holz O, Smith R, Bruin G, Koehne-Voss S, Magnussen H, Waltz DA
Eur Respir J. 2013 Jan; 41(1):239-41. PMID: 23277522. Abstract
Administration: 
Intravenous; doses ranged from 3 to 10 mg per kg, given as a 2-hour intravenous infusion either once or twice (3 weeks apart) in clinical studies
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Given in monthly subcutaneous injections (25 mg to 300 mg) in a clinical trial for rheumatoid arthritis
(20)
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee S-H, Codding CE, Kellner H, et al.
Ann Rheum Dis. 2013 Jun; 72(6):863-9. Epub 2012 Jun 23. PMID: 22730366. Abstract
Negative effects: 
Generally appears safe in proof-of-concept studies
(1)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, et al.
Sci Transl Med. 2010 Oct 6; 2(52):52ra72. PMID: 20926833. Abstract
Infections
(14)
Secukinumab shines in small MS trial
Gever J, Medpage Today, 13 Oct 2012
Accessed on 28 Oct 2013 from http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/35300.
Commercial: 
Developed by Novartis Pharmaceuticals
(23)
Biologics at Novartis
Novartis
Accessed on 29 Oct 2013 from http://www.nibr.com/cs/groups/public/@nibr_com/documents/document/n_prod_200370.pdf.
Clinical trials have been sponsored by Novartis Pharmaceuticals
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Approved in Japan for treating adults with psoriasis or psoriatic arthritis (26 December 2014)
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Approved in the US and EU for treating moderate-to-severe plaque psoriasis (early 2015)
(26)
Secukinumab: first global approval.
Sanford M, McKeage K
Drugs. 2015 Feb; 75(3):329-38. PMID: 25648267. Abstract
Key Clinical Trials
Placebo-controlled Trials: 
Trial name: 
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Phase: 
Phase II trial
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Study Design: 
Industry-sponsored, multicenter, placebo-controlled, randomized, double-blind, parallel group, adaptive dose-ranging trial to study the safety and effects of secukinumab on the cumulative number of new gadolinium-enhancing lesions (primary outcome measure) and the annualized relapse rate (a secondary outcome measure
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Disease Stage: 
RRMS
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Enrollment/Number of Patients: 
380 (estimated)
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Duration: 
6 months
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Status/Outcome: 
Recruiting as of September 2013; estimated study completion date is October 2015
(11)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov, 11 Sep 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01874340.
Trial name: 
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis (meeting report, October 2012)
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
(14)
Secukinumab shines in small MS trial
Gever J, Medpage Today, 13 Oct 2012
Accessed on 28 Oct 2013 from http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/35300.
Phase: 
Phase II trial
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Study Design: 
Industry-sponsored, multicenter, placebo-controlled, randomized, double-blind, proof-of-concept trial to study the effects of secukinumab [10 mg per kg infused intravenously, once every 2 weeks (first 3 doses) and then once every 4 weeks (through week 20)] on the number of combined unique activity brain lesions (a combination of new gadolinium-enhancing T1 lesions and new or growing T2 lesions) (primary outcome)
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
(14)
Secukinumab shines in small MS trial
Gever J, Medpage Today, 13 Oct 2012
Accessed on 28 Oct 2013 from http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/35300.
Disease Stage: 
RRMS
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Enrollment/Number of Patients: 
73
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Duration: 
24 weeks
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Status/Outcome: 
Final data collection date for the primary outcome measure was April 2012
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
; over weeks 12 to 24, secukinumab was associated with a 63% reduction in the number of cumulative combined unique activity lesions relative to placebo (but over weeks 4 to 24, the difference was not statistically significant); secukinumab was associated with more moderately serious infections than placebo
(14)
Secukinumab shines in small MS trial
Gever J, Medpage Today, 13 Oct 2012
Accessed on 28 Oct 2013 from http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/35300.
Head-to-Head Trials: 
Other Trials: 
Trial name: 
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Phase: 
Extension of Phase II trial
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
(13)
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 27 Apr 2012
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01051817.
Study Design: 
Industry-sponsored, open-label extension study to examine the number of participants with adverse events (primary outcome measure) when a group of participants is treated with secukinumab, as well as the effects of secukinumab on the relapse rate and disability progression (secondary outcome measures)
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Disease Stage: 
RRMS
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Enrollment/Number of Patients: 
40 (estimated)
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Duration: 
1 year
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Status/Outcome: 
Recruiting as of May 2013; estimated completion date is June 2014
(12)
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov, 9 May 2013
Accessed on 28 Oct 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01433250.
Trial name: 
Chioato et al., Clin. Vaccine Immunol., October 2012 study
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
Phase: 
Observational/open-label study
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
Study Design: 
Industry-sponsored, single-center, open-label, parallel-group, randomized study to examine whether secukinumab (single 150 mg dose), relative to no treatment, interferes with the efficacy of influenza and meningococcal vaccines given 2 weeks later
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
Disease Stage: 
Healthy individuals
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
Enrollment/Number of Patients: 
50
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
Duration: 
6 weeks
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
Status/Outcome: 
Secukinumab does not appear to affect the efficacy or either vaccine, as judged by protective antibody levels
(15)
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H
Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602. Epub 2012 Aug 08. PMID: 22875601. Abstract
References
ChemIDplus Advanced
United States National Library of Medicine
Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp.

Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.

Biologics at Novartis
Novartis
Accessed on 29 Oct 2013 from http://www.nibr.com/cs/groups/public/@nibr_com/documents/document/n_prod_200370.pdf.
DOI: 
doi/10.7493/msdf.10.8239.1